Skip to main content

Table 3 Genes that have a general association (P-value < 0.05) with the lifetime glioblastoma survival

From: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival

Gene Symbol Probe Identifier P-value Hazard Ratio1 Relevant literature references
Syne1 209447_at <.0001 0.17 (0.10-0.32) [60]O
E2f3 203692_s_at <.0001 0.26 (0.15-0.44) [28]G
Fstl1 208782_at <.0001 0.31 (0.22-0.42) [25]G
Ep300 213579_s_at <.0001 0.34 (0.29-0.57) [26]G
Gigyf2 212261_at <.0001 0.39 (0.26-0.58) n/a
Topors 204071_s_at <.0001 0.41 (0.29-0.59) [26]G
Chst4 220446_s_at 0.09892 0.44 (0.17-1.16) [89]O
Sar1a 201543_s_at <.0001 0.44 (0.29-0.66) n/a
Il13ra1 210904_s_at <.0001 0.47 (0.36-0.60) [24]G
Sod2 221477_s_at <.0001 0.47 (0.37-0.59) [25]G
Rab15 221810_at <.0001 0.48 (0.34-0.69) n/a
Timm23 218118_s_at 0.0239 0.50 (0.27-0.91) n/a
Kcnj4 208359_s_at <.0001 0.50 (0.38-0.66) n/a
Rpl37a 213459_at 0.0023 0.51 (0.33-0.79) [90]G
Camk2g 214322_at 0.0135 0.53 (0.32-0.88) [56]G
Plcg1 216551_x_at 0.0068 0.55 (0.35-0.85) [26]G
Slc43a3 213113_s_at 0.0004 0.56 (0.40-0.77) n/a
Cdc42 208727_s_at <.0001 0.57 (0.45-0.73) [26]G
Csf1 207082_at 0.0092 0.58 (0.38-0.88) [26]G
Ccnb2 202705_at 0.0118 0.60 (0.40-0.89) [91]G
Tlk2 212997_s_at 0.0004 0.64 (0.49-0.82) n/a
Mtap 204956_at 0.0091 0.67 (0.49-0.91) [26]G
Egfr 211551_at 0.07432 0.68 (0.45-1.04) [24]G
Akt2 211453_s_at 0.0292 0.68 (0.48-0.96) [86]G
Akr1c3 209160_at <.0001 0.70 (0.62-0.81) [26]G
Tp53 211300_s_at 0.0215 0.76 (0.60-0.96) [25]G
Igf1 209541_at 0.0183 0.76 (0.61-0.95) [26]G
Rpl10 221989_at 0.0392 0.80 (0.64-0.99) [24]G
Arhgef4 205109_s_at 0.06472 0.80 (0.64-1.01) n/a
Cdc42 214230_at 0.05542 0.82 (0.67-1.00) [26]G
Chi3l1 216546_s_at 0.061 0.87 (0.75-1.00) [70]G
Ppbp 214146_s_at 0.012 1.16 (1.03-1.30) n/a
Cdkn2a 209644_x_at 0.0003 1.18 (1.08-1.29) [92]G
Wdr67 214061_at 0.0237 1.30 (1.03-1.63) [93]O
Tspyl5 213122_at 0.0003 1.34 (1.14-1.56) n/a
Usf2 215737_x_at <.0001 1.42 (1.19-1.69) [94]O
Camk2g 212757_s_at 0.0078 1.54 (1.12-2.13) [56]G
Pik3r1 212240_s_at 0.0022 1.67 (1.20-2.32) [20]G
Akt1 207163_s_at 0.0005 1.70 (1.26-2.30) [84]O
Rac2 213603_s_at 0.0001 1.74 (1.31-2.31) [95]G
Six6 207250_at <.0001 1.82 (1.45-2.28) [96]O
Spg21 217827_s_at 0.0387 1.91 (1.03-3.52) n/a
Wdyhv1 219060_at 0.0015 1.95 (1.29-2.94) n/a
Uros 203031_s_at 0.0067 2.37 (1.27-4.42) n/a
Lin7c 219399_at 0.0002 2.40 (1.51-3.80) [97]O
Ros1 207569_at <.0001 2.58 (1.73-3.85) [98]O
Cdk2 204252_at <.0001 2.74 (1.78-4.21) [91]G
Jag2 32137_at <.0001 2.78 (1.86-4.14) [24]G
Kiaa0090 212395_s_at <.0001 2.89 (1.87-4.47) n/a
Ccnb1 214710_s_at <.0001 3.16 (2.00-4.98) [91]G
Scn5a 207413_s_at <.0001 3.21 (1.79-5.74) n/a
Col14a1 212865_s_at <.0001 3.30 (1.93-5.63) [99]O
Hoxa10 213147_at <.0001 3.30 (1.93-5.65) [100]O
Cdc42 208728_s_at <.0001 3.94 (2.12-7.32) [26]G
Pdcd4 202731_at <.0001 4.68 (3.01-7.28) [26]G
  1. n/a, No association with any type of cancer found in literature;
  2. 1 Hazard ratio estimate (95% confidence interval);
  3. 2 Borderline significant (P-value < 0.1) included for completeness;
  4. G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
  5. O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.